cationic lipid

DOTAP chloride (1, 2-dioleoyl-3-trimethylammonium-propane chloride) is an efficient cationic lipid, and its target is mainly the negatively charged components on the cell membrane. DOTAP chloride binds to negatively charged nucleic acids (such as DNA and RNA) by electrostatic interaction to form complexes, thereby achieving the delivery of nucleic acids.

DOTMA (N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium) is a tetra-methylated DOTA analogue. DOTMA is a cationic lipid and can be used as a non-viral vector for gene therapy. It has been used as a component in liposomes that can be used to encapsulate siRNA, microRNAs, and oligonucleotides and for gene transfection in vitro. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome- cell membrane interaction.

C12-200 is a five-tail/branched ionizable cationic lipid that serves as a benchmark lipid material in RNA delivery, demonstrating exceptional performance in mRNA and siRNA lipid nanoparticle (LNP) formulations.

D-Lin-MC3-DMA is a siRNA delivery vector, an ionizable amino-lipid compound. D-Lin-MC3-DMA offers advantages of high loading efficiency, low toxicity, and efficient endosomal escape.

5A2-SC8 is an ionizable cationic lipid that is an ideal vehicle for the delivery of small RNAs, interacts with negatively charged cell membranes, and can be used for gene delivery and drug delivery.

ALC-0315 is an ionizable cationic lipid that serves as a core component of lipid nanoparticle (LNP) delivery systems for mRNA vaccines, responsible for efficiently encapsulating, protecting, and delivering nucleic acids into cells. Lipid nanoparticles have already been used in research on mRNA (COVID-19) vaccines.

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

DLinDAP (D-LinDAP) is an ionizable cationic lipid used for SiRNA delivery.

DODAP is an ionic cationic lipid with low cytotoxicity and high transfection efficiency that can be used to synthesize liposomes and encapsulate biologically active molecules such as mRNA, siRNA and plasmid DNA.

7-Oxotridecanedioic Acid is a biodegradable cationic lipid intermediate for formulating active-agent-loaded lipid nanoparticles.

G0-C14 HCl is the salt form of G0-C14, a cationic lipid molecule and amphiphilic dendritic macromolecule commonly used in the synthesis of nanoparticles and vaccine delivery.

DOPE (DOPE) is a neutral helper lipid for cationic liposomes.It is used in combination with cationic phospholipids to increase efficiency during DNA transfection studies as a non-viral method of gene delivery.

IR-117-17 is an ionizable cationic amino lipid that targets the airways. It is degradable via esterase cleavage, making it less likely to accumulate with repeated dosing.

Ionizable Lipid 4 is an ionizable cationic lipid that forms as a product of the rearrangement of cationic lipid CA-lipid 5 under hydrogen peroxide induction.

BAmP-O16B is an ionizable cationic amino lipid utilized for the production of lipid nanoparticles (LNPs).

Lipid 23 is an ionizable cationic amino lipid used for the creation of lipid nanoparticles (LNP) and the delivery of mRNA.

L202 is an ionizable cationic lipid (pKa=6.04) utilized in the study of mRNA and lipid nanoparticles.

IM21.7c is a cationic lipid utilized in the synthesis of lipid nanoparticles (LNP) for the delivery of mRNA and other effective payloads.

C14-A1 is an ionizable cationic lipid utilized in the synthesis of lipid nanoparticles (LNP), which are employed for delivering mRNA and various other payloads.

C14-O2 is an ionizable cationic lipid utilized in the synthesis of lipid nanoparticles (LNP) for the delivery of mRNA and other payloads.

YHS-12, a ionizable cationic lipid (pKa = 6.506), has been utilized both in vitro and in vivo for delivering siRNA and mRNA via lipid nanoparticles (LNPs). These LNPs comprise YHS-12 and a targeting peptide CRVLRSGSC aimed at macrophages, encapsulating chimeric antigen receptor mRNA targeted at methicillin-resistant Staphylococcus aureus (MRSA) and siRNA against caspase-11. The LNPs have enhanced the phagocytic efficiency against MRSA in RAW 264.7 macrophages and primary murine bone marrow-derived macrophages (BMDMs). Administered intravenously, these LNPs have reduced bacterial load in the bloodstream and increased survival rates in a sepsis model in cyclophosphamide-induced immunosuppressed mice.

Lipid N2-3L is an ionizable cationic lipid with a pKa of 8.99, utilized in the formation of supramolecular lipid nanoparticles (SMLNPs) for enclosing mRNA in both in vitro and in vivo applications. Lipid N2-3L-containing SMLNPs accumulate at the injection site and draining lymph nodes in mice, featuring a luciferase reporter gene. Additionally, SMLNPs made with Lipid N2-3L that encapsulate ovalbumin mRNA and the Toll-like receptor 7/8 (TLR7/8) agonist R-848 serve as adjuvants. These enhance dendritic cell maturation and antigen presentation, reducing tumor volume and increasing survival rates in MC-38-OVA colon cancer mouse models.

Lipid 29 is an unsaturated, ionizable cationic lipid that facilitates the formation of lipid nanoparticles (LNP) used for intrabody mRNA delivery. When integrated into LNPs encapsulating luciferase reporter gene mRNA, intravenous injection of these LNPs induces bioluminescence in the lungs and spleen of mice.

L-369 is an ionizable cationic lipid.